VATS lobectomy
ProcedureVATS lobectomy
NCT Number: NCT04799509
A five classes (A-E) aggregate risk score predicting 90-day mortality after video-assisted thoracoscopic lobectomy for lung cancer, including as independent factors male sex (3 points), carbon monoxide lung diffusion capacity <60% (1 point) and operative time >150 minutes (1 point), has been recently published. This study aims to assess the effectiveness and reliability of this risk model in a large, independent cohort of patients, in order to confirm its generalizability.
Looking for future studies?
Notify MeAll sexes
Observational
From the Italian VATS Group Database, we selected patients who underwent video-assisted thoracoscopic lobectomy for non-small cell lung cancer. We calculated the aggregate risk score and the corresponding class of 90-day mortality risk for each patient. The correlation between risk classes and mortality rates was tested by Spearman's rho-test. Model calibration was evaluated by Hosmer-Lemeshow goodness-of-fit test.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
VATS lobectomy
Time frame: 90 day post surgical procedure
Alive/Death (cause of death)
Università degli Studi dell'Insubria
Other
Assessment of the 90-day Mortality Risk Score After Video-assisted Thoracoscopic Lobectomy in the Italian VATS Group Cohort
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04939324
Bronchial Neoplasms, Carcinoma, Bronchogenic
Limoges, France
View Trial DetailsNCT04262856
Bronchial Neoplasms, Carcinoma, Bronchogenic
Birmingham, Alabama, United States
View Trial DetailsNCT01421953
Bronchial Neoplasms, Carcinoma, Bronchogenic
Bordeaux, France
View Trial DetailsNCT05928299
Bronchial Neoplasms, Carcinoma, Bronchogenic
Guangzhou, Guangdong, China
View Trial Details